FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2099842398> ?p ?o ?g. }

• W2099842398 endingPage "1049" @default.
• W2099842398 startingPage "1048" @default.
• W2099842398 abstract ", We report two patients on etanercept who presented withsevere diffuse alveolar infiltrates culminating in ground-glasschange on high resolution computed tomography (HRCT) of thelung.The first, a 64-yr-old woman with an 11-yr-history of sero-negative rheumatoid arthritis (RA) had failed to achieve optimalcontrol of her RA with multiple disease modifying antirheumaticdrugs (DMARDs) and only showed a partial response to oralmethotrexate 22.5mg/week since 2002. Etanercept was introducedat 25mg twice a week. She developed acute breathlessness after sixinjections (3 weeks).She was an ex-smoker who had stopped 10yrs previously. Shehad no pre-existing rheumatoid lung disease but did have chronicobstructive pulmonary disease (COPD). Full pulmonary functiontests done 5yrs earlier showed the evidence of previous chronicobstructive airways disease, her corrected transfer factor (DLCO)corrected was 13.18 (55%) with a KCO 2.86 (62%). Chest X-ray(CXR) showed emphysema.She was admitted with a 3-day history of increasing shortness ofbreath (SOB) at rest without cough. HRCT of the chest showedwidespread ground-glass change throughout both lung bases, andchanges of bullous emphysema.Etanercept was discontinued. She was commenced on 40mgoral prednisolone and broad-spectrum antibiotics. Her SOBrecovered quickly but her joint symptoms flared and she wasrestarted on oral methotrexate 25mg/week to good effect. RepeatHRCT scan after 4 months showed significant improvement inground-glass changes with some minimal residual interstitialfibrotic change and bullae.The second case, a 61-yr-old lady, with RA for 10 yrs similarlyhad failed multiple DMARDS. A methotrexate dose of 25mg hadbeen started in 1999. She had known rheumatoid lung disease, andprevious pulmonary function tests showed restrictive lung diseasewith DLCO 2.06 (33%) and KCO 1.02 (63%). HRCT chestscan 1yr earlier prior to treatment showed pulmonary fibrosissuggestive of UIP, with no ground-glass change.She presented with a 2-week-history of breathlessness after 12injections (6 weeks) of etanercept, 25mg twice a week. There wasno evidence of infection or heart failure. CXR showed new diffusereticulonodular shadowing. CT pulmonary angiography (CTPA)confirmed widespread ground-glass change with no evidence ofpulmonary embolism.She was treated with broad spectrum intravenous antibiotics.The etanercept and methotrexate were stopped. Despite this andadding methylprednisolone 500mg/day for 3 days and changingantibiotics, she developed worsening hypoxia and was intubated.Bronchoalveolar lavage showed no evidence of TB, bacterial orpneumocystis Carinii infection.She developed metabolic acidosis, progressive renal failure andlater cardiacarrhythmias,anddespiteintensivetreatmentshe died.Both our patients had pre-existing lung disease, they hadenquiry into respiratory symptoms at 3 month intervals andannual CXR prior to the commencement of etanercept and weresymptomatically stable. Also,both wereonmethotrexate andbothdeveloped acute respiratory symptoms within 3 and 6 weeks ofcommencing etanercept, respectively, which culminated in accel-erated interstitial lung disease. The patient with COPD presentedearlier and recovered quickly with oral steroids aloneafter discontinuing etanercept and subsequently was able torecommence methotrexate 25mg/week with adequate joint diseasecontrol but no recurrence of respiratory symptoms. The patientwith poorer respiratory reserve developed progressive lung diseaseand died despite aggressive treatment.Lungdiseaseisawell-knowncomplicationofmethotrexate,andcases of accelerated methotrexate pneumonitis are also reportedwithin 2–3 doses of infliximab. Our patient who survived restartedmethotrexate safely, hence we do not postulate this as a cause [1].Infliximab has been reported to accelerate lung nodulosis [2, 3],and it has been reported as causing a reversible, biopsy proven,non-caseating granulomatous lung disease in RA [4]. In both ourpatients, lung biopsies were taken, which may have been thehistological change of the respiratory disease. Four further casesof reversible non-caseating granulomatous reaction temporallyrelatedtoetanercepttherapyhavealsobeenreported,twoofwhichhad previous pulmonary fibrosis [5]. Our two cases demonstrate alittle-known complication of etanercept, one of which was fatal. Itis noticeable that the patient who died also had rheumatoid lungdisease, whilst the patient with COPD survived. Previously reportsfrom the Biologics register [6], and published reports have raisedthe concern of increased mortality in patients with RA andpre-existing rheumatoid lung disease on azathiaprine whenanti-TNF was added [7]. On the basis of these two cases cautionneeds to be extended to those with pre-existing lung disease, takingmethotrexate when etanercept is added, particularly if the lungdisease is due to rheumatoid involvement. Extra caution should betaken in patients with rheumatoid lung and poor respiratoryreserve. Patients should be prompted to contact the rheumatologydepartment if symptoms of acute breathlessness occur, especiallysoon after the introduction of etanercept.The authors have declared no conflict of interest.K. L" @default.
• W2099842398 created "2016-06-24" @default.
• W2099842398 creator A5045336141 @default.
• W2099842398 creator A5055594383 @default.
• W2099842398 creator A5073052289 @default.
• W2099842398 creator A5076600050 @default.
• W2099842398 date "2006-06-07" @default.
• W2099842398 modified "2023-10-16" @default.
• W2099842398 title "Acute progression of interstitial lung disease: a complication of etanercept particularly in the presence of rheumatoid lung and methotrexate treatment" @default.
• W2099842398 cites W2010486384 @default.
• W2099842398 cites W2023007609 @default.
• W2099842398 cites W2023705446 @default.
• W2099842398 cites W2061038549 @default.
• W2099842398 cites W2064370469 @default.
• W2099842398 cites W2149396544 @default.
• W2099842398 doi "https://doi.org/10.1093/rheumatology/kel090" @default.
• W2099842398 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16760195" @default.
• W2099842398 hasPublicationYear "2006" @default.
• W2099842398 type Work @default.
• W2099842398 sameAs 2099842398 @default.
• W2099842398 citedByCount "50" @default.
• W2099842398 countsByYear W20998423982012 @default.
• W2099842398 countsByYear W20998423982013 @default.
• W2099842398 countsByYear W20998423982014 @default.
• W2099842398 countsByYear W20998423982015 @default.
• W2099842398 countsByYear W20998423982017 @default.
• W2099842398 countsByYear W20998423982018 @default.
• W2099842398 countsByYear W20998423982019 @default.
• W2099842398 countsByYear W20998423982020 @default.
• W2099842398 countsByYear W20998423982021 @default.
• W2099842398 countsByYear W20998423982022 @default.
• W2099842398 crossrefType "journal-article" @default.
• W2099842398 hasAuthorship W2099842398A5045336141 @default.
• W2099842398 hasAuthorship W2099842398A5055594383 @default.
• W2099842398 hasAuthorship W2099842398A5073052289 @default.
• W2099842398 hasAuthorship W2099842398A5076600050 @default.
• W2099842398 hasBestOaLocation W20998423981 @default.
• W2099842398 hasConcept C126322002 @default.
• W2099842398 hasConcept C2777226972 @default.
• W2099842398 hasConcept C2777543607 @default.
• W2099842398 hasConcept C2777575956 @default.
• W2099842398 hasConcept C2777714996 @default.
• W2099842398 hasConcept C2779134260 @default.
• W2099842398 hasConcept C2781059491 @default.
• W2099842398 hasConcept C71924100 @default.
• W2099842398 hasConcept C81182388 @default.
• W2099842398 hasConceptScore W2099842398C126322002 @default.
• W2099842398 hasConceptScore W2099842398C2777226972 @default.
• W2099842398 hasConceptScore W2099842398C2777543607 @default.
• W2099842398 hasConceptScore W2099842398C2777575956 @default.
• W2099842398 hasConceptScore W2099842398C2777714996 @default.
• W2099842398 hasConceptScore W2099842398C2779134260 @default.
• W2099842398 hasConceptScore W2099842398C2781059491 @default.
• W2099842398 hasConceptScore W2099842398C71924100 @default.
• W2099842398 hasConceptScore W2099842398C81182388 @default.
• W2099842398 hasIssue "8" @default.
• W2099842398 hasLocation W20998423981 @default.
• W2099842398 hasLocation W20998423982 @default.
• W2099842398 hasOpenAccess W2099842398 @default.
• W2099842398 hasPrimaryLocation W20998423981 @default.
• W2099842398 hasRelatedWork W2029474929 @default.
• W2099842398 hasRelatedWork W2058435704 @default.
• W2099842398 hasRelatedWork W2083278471 @default.
• W2099842398 hasRelatedWork W2106806370 @default.
• W2099842398 hasRelatedWork W2138243862 @default.
• W2099842398 hasRelatedWork W2314052274 @default.
• W2099842398 hasRelatedWork W2314544353 @default.
• W2099842398 hasRelatedWork W2411121127 @default.
• W2099842398 hasRelatedWork W4283524728 @default.
• W2099842398 hasRelatedWork W2314697596 @default.
• W2099842398 hasVolume "45" @default.
• W2099842398 isParatext "false" @default.
• W2099842398 isRetracted "false" @default.
• W2099842398 magId "2099842398" @default.
• W2099842398 workType "article" @default.